# Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

> **NCT07567014** · PHASE2 · NOT_YET_RECRUITING · sponsor: **NYU Langone Health** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Myeloma
- Large B-cell Lymphoma (LBCL)

## Interventions

- **DRUG:** Emapalumab

## Key facts

- **NCT ID:** NCT07567014
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-11
- **Primary completion:** 2028-05-31
- **Final completion:** 2029-05-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07567014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07567014, "Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07567014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*